ETF profile for Virtus Biotech Clinical Trials ETF (BBC) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
BBC ETF Profile
| Family: |
Virtus ETF Solutions |
| Name: |
Virtus Biotech Clinical Trials ETF |
|
|
| Inception Date: |
17-Dec-2014 |
| Termination Date: |
|
| Investment Objective: |
Virtus Biotech Clinical Trials ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index (the "Underlying Index"). Under normal market conditions, the Fund will invest not less than 80% of its assets in component securities of the Underlying Index. The Underlying Index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The Underlying Index is sponsored by LifeSci Index Partners, LLC (the "Index Provider"). The Index Provider utilizes a selection committee comprised of its employees that is responsible, pursuant to the rules included in the methodology for the Underlying Index, for making certain determinations for the Underlying Index. The Index Committee utilizes various public data sources to make determinations, including, but not limited to, Securities and Exchange Commission ("SEC") filings, public documents from the U.S. Food and Drug Administration ("FDA"), company press releases and official corporate websites. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| Kodiak Sciences Inc |
KOD |
2.0861% |
| First Tracks Biotherapeutics Inc |
TRAX |
2.0246% |
| AbCellera Biologics Inc |
ABCL |
1.8289% |
| Xencor Inc |
XNCR |
1.6558% |
| Amylyx Pharmaceuticals Inc |
AMLX |
1.5116% |
| ORIC Pharmaceuticals Inc |
ORIC |
1.2912% |
| SpyGlass Pharma Inc |
SGP |
1.2523% |
| Nurix Therapeutics Inc |
NRIX |
1.2121% |
| SELLAS Life Sciences Group Inc |
SLS |
1.1950% |
| VeraDermics Inc |
MANE |
1.1712% |
|
Top 10 Holdings Weight: |
15.2% |
| Number of Holdings: |
130 |
| Shares Outstanding: |
950,004 |
| Total Net Assets: |
39,009,920 |
| NAV: |
41.18 |
| Net Expense Ratio: |
0.65% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
US |
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Domestic |
